 |
 |
|
|
RESÚMENES MARZO 2005 |
Psychotic Disorders & Antipsychotics
(Requiere estar conectado a internet. Haga un click en la
información del journal)
Inhibition of
System A-mediated glycine transport in cortical synaptosomes by therapeutic
concentrations of clozapine: implications for mechanisms of action
Rob W. Kerwin and Anusha Bolonna
Advances in Psychiatric
Treatment (2005) 11: 101-106
V. Molina, J. Sanz, S. Reig, R. Martínez, F. Sarramea, R. Luque, C.
Benito, J. D. Gispert, J. Pascau, and M. Desco
The British Journal of Psychiatry (2005) 186: 203-208
Nicotine dependence and symptoms in schizophrenia. Naturalistic study of complex interactions
M. Carmen Aguilar, Manuel Gurpegui, Francisco J. Diaz, Jose De Leon
The British Journal of Psychiatry (2005) 186: 215-221
David Taylor
Psychiatric Bulletin (2005) 29: 104-107
Antipsychotics
alter the protein expression levels of β-catenin and GSK-3 in the rat
medial prefrontal cortex and striatum
Heidar Alimohamad,
Nagalingam Rajakumar, Yam-Hong Seah and Walter Rushlow
Biological Psychiatry. Volume 57, Issue 5, 1 March 2005, Pages
533-542
A comparison of
electronic monitoring vs. clinician rating of antipsychotic adherence in
outpatients with schizophrenia
Matthew Byerly,
Robert Fisher, Katrina Whatley, Rhiannon Holland, Femina Varghese, Thomas
Carmody, Brianne Magouirk and A. John Rush
Psychiatry Research. Volume 133, Issues 2-3, 28 February 2005,
Pages 129-133
Martin Brüne
Psychiatry Research. Volume 133, Issues 2-3, 28 February 2005,
Pages 135-147
Sandrine Louchart-de la Chapelle, Irène Nkam, Emmanuelle Houy,
Angélique Belmont, Jean-François Ménard, Anne-Claire Roussignol, Ophélie Siwek,
Mustapha Mezerai, Marion Guillermou, Gaël Fouldrin, Daniel Levillain, Sonia
Dollfus, Dominique Campion, and Florence Thibaut
Am J Psychiatry 162:466-474,
March 2005
Low Gene
Expression Conferred by Association of an Allele of the 5-HT2C
Receptor Gene With Antipsychotic-Induced Weight Gain
Paul R. Buckland, Bastiaan Hoogendoorn, Carol A. Guy, S. Kaye Smith,
Sharon L. Coleman, and Michael C. O’Donovan
Am J Psychiatry 162:613-615, March 2005
Volume Changes in Gray Matter in First-Episode Neuroleptic-Naive
Schizophrenic Patients Treated With Risperidone.
Massana, Guillem; Salgado-Pineda, Pilar;
Junque, Carme; Perez, Merce; Baeza, Immaculada; Pons, Alexandre; Massana, Joan;
Navarro, Victor; Blanch, Jordi; Morer, Astrid; Mercader, Jose Maria; Bernardo,
Miquel
Journal of Clinical Psychopharmacology. 25(2):111-117,
April 2005
Low-Dose Fluvoxamine as an Adjunct to Reduce Olanzapine Therapeutic Dose
Requirements: A Prospective Dose-Adjusted Drug Interaction Strategy.
Albers, Lawrence J.; Ozdemir, Vural;
Marder, Stephen R.; Raggi, Maria Augusta; Aravagiri, Manickam; Endrenyi,
Laszlo; Reist, Christopher
Journal of Clinical Psychopharmacology. 25(2):170-174,
April 2005
Maintenance Treatment of Severe Tardive Dyskinesia With Clozapine: 5
Years' Follow-up.
Louza, Mario Rodrigues; Bassitt, Debora
Pastore
Journal
of Clinical Psychopharmacology. 25(2):180-182, April 2005
The Lifetime Risk of Suicide in Schizophrenia. A Reexamination
Brian
A. Palmer, V. Shane Pankratz, John Michael Bostwick
Arch Gen Psychiatry. 2005;62:247-253
Safety of Haloperidol and Penfluridol in Pregnancy: A
Multicenter, Prospective, Controlled Study
Orna Diav-Citrin,
Svetlana Shechtman, Shani Ornoy, Judy Arnon, Christof
Schaefer, Hanneke Garbis, Maurizio Clementi, and Asher Ornoy
J Clin Psychiatry 2005;66:317-322
Horacio Preval,
Steven G. Klotz, Robert Southard, Andrew Francis
Gen Hosp Psychiatry. Vol 27, Issue 2, Pages 140-144 (March
2005)
Ziprasidone and haloperidol in the treatment of acute exacerbation of
schizophrenia and schizoaffective disorder: comparison of intramuscular and
oral formulations in a 6-week, randomized, blinded-assessment study
Shlomo Brook,
Jeorg Walden, Isma Benattia, Cynthia O. Siu and
Steven J. Romano
Psychopharmacology 2005; Volume 178, Number
4: 514 - 523
Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction
Deepak Cyril
D’Souzaa, Walid Michel Abi-Saab, Steven Madonick, Kimberlee Forselius-Bielen,
Anne Doersch, Gabriel Braley, Ralitza Gueorguieva, Thomas B. Cooper and John
Harrison Krystal
Biological Psychiatry. Volume 57, Issue 6 , 15 March 2005, Pages
594-608
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia
Uriel Heresco-Levy,
Daniel C. Javitt, Richard Ebstein, Agnes Vass, Pesach Lichtenberg, Gali Bar,
Sara Catinari and Marina Ermilov
Biological Psychiatry. Volume 57, Issue 6 , 15 March 2005, Pages
577-585
Dimensions and
classes of psychosis in a population cohort: a four-class, four-dimension model
of schizophrenia and affective psychoses
V. MURRAY,
I. McKEE, P. M. MILLER, D. YOUNG, W. J. MUIR, A.
J. PELOSI and D. H. R. BLACKWOOD
Psychological Medicine (2005), 35:4:499-510
Predicting features of later development of schizophrenia among patients
with acute and transient psychotic disorder
KIYOKO SUDA, NAOKI HAYASHI, AND MASAJI HIRAGA
Psychiatry and Clinical Neurosciences. Volume
59 Issue 2 Page 146 - April 2005
JEE-YEON KIM, IN-KWA JUNG, CHANGSU HAN, SOOK-HAENG CHO, LEEN KIM,
SEUNG-HYUN KIM, BUN-HEE LEE, HEON-JEONG LEE, AND YONG-KU KIM
Psychiatry and Clinical Neurosciences. Volume
59 Issue 2 Page 183 - April 2005
Influence of duration of untreated psychosis on auditory P300 in
drug-naive and first-episode schizophrenia
JIJUN WANG, YOSHIO HIRAYASU, HIROTO HOKAMA, SHIN
TANAKA, TSUYOSHI KONDO, MINGDAO ZHANG, AND ZEPING XIAO
Psychiatry and Clinical Neurosciences. Volume
59 Issue 2 Page 209 - April 2005
A
meta-analysis of neuropsychological change to clozapine, olanzapine,
quetiapine, and risperidone in schizophrenia.
Woodward ND, Purdon SE,
Meltzer HY, Zald DH